• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Microorganisms . Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG

tetano

Editor, Senior Moderator
Microorganisms


. 2021 Mar 31;9(4):733.
doi: 10.3390/microorganisms9040733.
Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG


Kirsten Alexandra Eberhardt[SUP] 1 2 [/SUP], Felix Dewald[SUP] 3 4 [/SUP], Eva Heger[SUP] 3 [/SUP], Lutz Gieselmann[SUP] 3 [/SUP], Kanika Vanshylla[SUP] 3 4 [/SUP], Maike Wirtz[SUP] 3 [/SUP], Franziska Kleipass[SUP] 3 [/SUP], Wibke Johannis[SUP] 5 [/SUP], Philipp Schommers[SUP] 3 6 7 [/SUP], Henning Gruell[SUP] 3 7 [/SUP], Karl August Brensing[SUP] 8 [/SUP], Roman-Ulrich M?ller[SUP] 4 9 10 [/SUP], Max Augustin[SUP] 6 [/SUP], Clara Lehmann[SUP] 4 6 7 [/SUP], Manuel Koch[SUP] 4 11 [/SUP], Florian Klein[SUP] 3 4 7 [/SUP], Veronica Di Cristanziano[SUP] 3 4 [/SUP]



Affiliations

Abstract

Background: The investigation of the antibody response to SARS-CoV-2 represents a key aspect in facing the COVID-19 pandemic. In the present study, we compared the new Immundiagnostik IDK? anti-SARS-CoV-2 S1 IgG assay with four widely-used commercial serological assays for the detection of antibodies targeting S (spike) and NC (nucleocapsid) proteins. Methods: Serum samples were taken from an unbiased group of convalescent patients and from a negative control group. Sample were simultaneously analyzed by the new Immundiagnostik IDK[SUP]?[/SUP] anti-SARS-CoV-2 S1 IgG assay, by the DiaSorin LIAISON[SUP]?[/SUP] SARS-CoV-2 S1/S2 IgG assay, and by the Euroimmun anti-SARS-CoV-2 S1 IgG ELISA. Antibodies binding NC were detected by the Abbott SARS-CoV-2 IgG assay and by the pan-immunoglobulin immunoassay Roche Elecsys[SUP]?[/SUP] anti-SARS-CoV-2. Moreover, we investigated samples of a group of COVID-19 convalescent subjects that were primarily tested S1 IgG non-reactive. Samples were also tested by live virus and pseudovirus neutralization tests. Results: Overall, the IDK? anti-SARS-CoV-2 S1 IgG assay showed the highest sensitivity among the evaluated spike (S) protein-based assays. Additionally, the Immundiagnostik assay correlated well with serum-neutralizing activity. Conclusions: The novel IDK[SUP]?[/SUP] anti-SARS-CoV-2 S1 IgG assay showed high sensitivity and specificity, representing a valid option for use in the routine diagnostic.

Keywords: COVID-19; antibody; coronavirus; humoral response; neutralization; non-responder; pandemic; protection; sensitivity; titer.
 
Back
Top Bottom